Is Monopar Therapeutics Inc. (MNPR) a Buy, Sell, or Hold?
Monopar Therapeutics Inc.
NASDAQ:MNPR
$99.79 USD
-$3.54 (-3.43%)
- Volume
- 0
- Average Volume
- 172.64K
- Market Capitalization
- $668.5M
- P/E Ratio
- -48.21
- Dividend Yield
- 0.00%
- Price Target
- $105.00
- Year High
- $112.57
- Year Low
- $29.18
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $56.04
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Chandler D. Robinson |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | MNPR |
| CUSIP | 61023L207 |
| CIK | 0001645469 |
| Web | https://www.monopartx.com |
| Phone | 847 388 0349 |
| Currency | USD |
| Employees | 22 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 56.04 |
| Quick Ratio | 56.04 |
| Cash Ratio | 21.38 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.17 |
| Price / Cash Flow | -66.77 |
| Price / Book | 6.29 |
Price Target and Rating
| Average Stock Price Forecast | $105.00 |
| High Stock Price Forecast | $117.00 |
| Low Stock Price Forecast | $105.00 |
| Forecast Upside/Downside | -4.96% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 13 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.85 |
| Trailing P/E Ratio | -48.21 |
| PEG Ratio | 1.71 |
| P/E Growth | 1.71 |
| Net Income | $-13.72M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -12.84% |
| Return on Assets | -10.86% |
Financials Score
| AltmanZ Score | 160.26 |
| Piotroski Score | 2.00 |
| Working Capital | 135.29M |
| Total Assets | 137.98M |
| Ebit | -15.64M |
| Market Cap | 692.21M |
| Total Liabilities | 2.59M |
Poll Results
About Monopar Therapeutics Inc. (NASDAQ:MNPR) Stock
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targetin ... g severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Monopar Therapeutics: ALXN1840's Bull Case Has Improved
2026-07-03 10:10:15
Monopar Therapeutics has evolved from early radiopharma assets into a more concrete bet with ALXN1840 for rare diseases. ALXN1840 is their Wilson disease asset, which currently has a much clearer regulatory path, FDA designations, and even a possible Priority Review Voucher. MNPR's financing also seems safer this time around as they prepare ALXN1840's NDA and subsequent potential launch.
2026-06-30 08:00:00
WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to ALXN1840 (tiomolibdate choline, TMC), the Company's late-stage candidate for the treatment of Wilson disease.
2026-06-26 16:05:00
WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new analyses from the Phase 3 FoCus randomized controlled clinical trial of ALXN1840 (tiomolibdate choline, TMC) will be presented at the 12th Congress of the European Academy of Neurology (EAN 2026), June 27–30, 2026, in Geneva, Switzerland. These analyses build upon the previously reported Phase 3 FoCus results demonstrating ALXN1840 met its primary endpoint of superior copper mobilization versus standard of care.
Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade
2026-06-15 10:55:30
The mean of analysts' price targets for Monopar Therapeutics (MNPR) points to an 88.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2026-06-01 07:00:00
WILMETTE, Ill., June 01, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the presentation (link) of Phase 2 ALXN1840-WD-205 data at the European Association for the Study of the Liver (EASL) Congress 2026. In a presentation titled “ALXN1840 (tiomolibdate choline) Stabilizes Liver Disease and Improves Neurological Symptoms as well as Quality of Life in Treatment-Experienced Wilson Disease Patients,” lead author Valentina Medici, MD, Professor of Medicine at the University of California Davis, presented results from the open-label, multicenter Phase 2 trial evaluating the effects of ALXN1840 on liver pathology and clinical outcomes in heavily pre-treated patients with Wilson disease.
2026-05-19 17:33:00
WILMETTE, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that Hepatology Communications has published a peer-reviewed manuscript entitled “Effect of Tiomolibdate Choline on Copper Balance in Patients with Wilson Disease: an Open-label Phase 2 Trial.”
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-14 14:00:00
WILMETTE, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced first quarter 2026 financial results and provided business updates.
2026-04-19 19:00:00
WILMETTE, Ill. , April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, announced new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) showing greater neurologic benefit versus standard of care (SoC) in Wilson disease patients with neurologic symptoms at baseline.
Frequently Asked Questions
-
What is the current Monopar Therapeutics Inc. (MNPR) stock price?
-
Monopar Therapeutics Inc.(NASDAQ:MNPR) stock price is $99.79 in the last trading session. During the trading session, MNPR stock reached the peak price of $112.57 while $29.18 was the lowest point it dropped to. The percentage change in MNPR stock occurred in the recent session was --3.43% while the dollar amount for the price change in MNPR stock was -$-3.54.
-
MNPR's industry and sector of operation?
-
The NASDAQ listed MNPR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MNPR?
-
Chandler D. Robinson | Co-Founder, Chief Executive Officer, President & Director
Andrew J. Cittadine | Chief Operating Officer
Susan Rodriguez | Chief Commercial & Strategy Officer
Christopher Starr | Co-Founder & Independent Executive Chairman of the Board
Quan Anh Vu | CFO, Principal accounting officer, Principal financial officer, Secretary & Treasurer -
How many employees does MNPR have?
-
Number of MNPR employees currently stands at 22. MNPR operates from 1000 Skokie Boulevard, Wilmette, IL 60091, US.
-
Link for MNPR official website?
-
Official Website of MNPR is: https://www.monopartx.com
-
How do I contact MNPR?
-
MNPR could be contacted at phone #847 388 0349 and can also be accessed through its website. MNPR operates from 1000 Skokie Boulevard, Wilmette, IL 60091, US.
-
How many shares of MNPR are traded daily?
-
The average number of MNPR shares traded daily for last 3 months was 172.64K.
-
What is the market cap of MNPR currently?
-
The market value of MNPR currently stands at $668.5M with its latest stock price at $99.79